Alexander Seryshev
Baylor College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alexander Seryshev.
Science Translational Medicine | 2012
Ming Shan; Xiaoyi Yuan; Li Zhen Song; Luz Roberts; Nazanin Zarinkamar; Alexander Seryshev; Yiqun Zhang; Susan G. Hilsenbeck; Seon Hee Chang; Chen Dong; David B. Corry; Farrah Kheradmand
The destruction of lung tissue in emphysema is orchestrated by antigen-presenting cells that have been activated by smoke. When Smoke Gets in Your Lungs Even without the warning label on the cigarette box, everyone knows that tobacco smoke is bad for you. But what really happens inside the lung to cause disease? Shan et al. have married studies in patients with emphysema and in mice exposed to tobacco smoke for several months to identify some of the crucial events that cause one serious lung disease—emphysema. They find that the antigen-presenting cells of the immune system are culpable; indeed, transfer of these cells from a mouse with emphysema into a healthy mouse induces disease. Further, they identify the signaling molecules in these cells that are activated by smoke (osteopontin and the transcription factor Irf7), which may prove to be useful targets for therapies. First, the authors verified that mice exposed to smoke carried similar immune cells in their lungs as do human smokers. These cells, including their secretory products IFN-γ and IL-17A, trigger the lung tissue destruction that robs emphysema patients of their ability to breathe. What activates these immune responses? The authors finger antigen-presenting cells by transferring these cells from diseased mice to healthy ones, showing that the disease transfers along with them. Then, tracing the process one step back, the authors look for smoke-induced genes in these antigen-presenting cells and identify osteopontin and Irf7, a transcription factor regulated by Spp1, as key mediators of smoke-induced cell activation. There are earlier steps in the process that have yet to be elucidated, but the cause of the havoc wreaked inside the lung by tobacco smoke is getting clearer. As a bonus, another cell type that participates in the mayhem unleashed in the emphysemic lung was uncovered. The γδ T cell, usually very rare, was unexpectedly found to be a good guy. Induced along with the destructive cells, these cells curtailed the damage but ultimately lost the battle. Perhaps bolstering the abilities of the helpful γδ T cells could ultimately help to treat serious immunogenic destructive processes in the lung. Smoking-related lung diseases are among the leading causes of death worldwide, underscoring the need to understand their pathogenesis and develop new effective therapies. We have shown that CD1a+ antigen-presenting cells (APCs) from lungs of patients with emphysema can induce autoreactive T helper 1 (TH1) and TH17 cells. Similarly, the canonical cytokines interferon-γ (IFN-γ) and interleukin-17A (IL-17A) are specifically linked to lung destruction in smokers, but how smoke activates APCs to mediate emphysema remains unknown. Here, we show that, in addition to increasing IFN-γ expression, cigarette smoke increased the expression of IL-17A in both CD4+ and γδ T cells from mouse lung. IL-17A deficiency resulted in attenuation of, whereas lack of γδ T cells exacerbated, smoke-induced emphysema in mice. Adoptive transfer of lung APCs isolated from mice with emphysema revealed that this cell population was capable of transferring disease even in the absence of active smoke exposure, a process that was dependent on IL-17A expression. Spp1 (the gene for osteopontin) was highly expressed in the pathogenic lung APCs of smoke-exposed mice and was required for the TH17 responses and emphysema in vivo, in part through its inhibition of the expression of the transcription factor Irf7. Thus, the Spp1-Irf7 axis is critical for induction of pathological TH17 responses, revealing a major mechanism by which smoke activates lung APCs to induce emphysema and identifying a pathway that could be targeted for therapeutic purposes.
Nature Immunology | 2009
Sangeeta Goswami; Pornpimon Angkasekwinai; Ming Shan; Kendra J. Greenlee; Wade T. Barranco; Sumanth Polikepahad; Alexander Seryshev; Li Zhen Song; D. Redding; Bhupinder Singh; Sanjiv Sur; Prescott G. Woodruff; Chen Dong; David B. Corry; Farrah Kheradmand
The innate immune response of airway epithelial cells to airborne allergens initiates the development of T cell responses that are central to allergic inflammation. Although proteinase allergens induce the expression of interleukin 25, we show here that epithelial matrix metalloproteinase 7 (MMP7) was expressed during asthma and was required for the maximum activity of interleukin 25 in promoting the differentiation of T helper type 2 cells. Allergen-challenged Mmp7−/− mice had less airway hyper-reactivity and production of allergic inflammatory cytokines and higher expression of retinal dehydrogenase 1. Inhibition of retinal dehydrogenase 1 restored the asthma phenotype of Mmp7−/− mice and inhibited the responses of lung regulatory T cells, whereas exogenous administration of retinoic acid attenuated the asthma phenotype. Thus, MMP7 coordinates allergic lung inflammation by activating interleukin 25 while simultaneously inhibiting retinoid-dependent development of regulatory T cells.
Cancer Chemotherapy and Pharmacology | 1999
Nadezhda Koshkina; Brain E. Gilbert; J. Clifford Waldrep; Alexander Seryshev; Vernon Knight
Purpose: The plant alkaloid camptothecin (CPT) has shown significant antitumor activity against a wide variety of human tumors xenografted in nude mice. In previous studies we have found that administration of dilauroylphosphatidylcholine (DLPC) liposome aerosols containing 9-nitrocamptothecin (9-NC) inhibits the growth of human breast, colon and lung cancer xenografts. The purpose of this study was to analyze the pharmacokinetics and tissue distribution of inhaled CPT formulated in DLPC liposomes. Methods: C57BL/6 mice with subcutaneous Lewis lung carcinoma, Swiss nu/nu mice with human lung carcinoma xenografts and BALB/c mice without tumors were used for pharmacokinetic studies of CPT administered as a liposome aerosol and BALB/c mice were given CPT intramuscularly. Results: After 30 min inhalation of CPT liposome aerosol, drug was deposited in the lungs (310 ng/g) and was followed promptly by the appearance of high concentrations in the liver (192 ng/g) and with lesser amounts appearing in other organs. Drug concentration in the brain was 61 ng/g. After intramuscular injection of CPT dissolved in DMSO, drug was released from the site of injection very slowly and accumulated mainly in the liver (136 ng/g). Only trace amounts appeared in the lungs (2–4 ng/g). These results demonstrate a prompt pulmonary and later systemic distribution of CPT following liposome aerosol administration. Conclusions: The substantial concentrations of CPT in lungs and other organs following inhalation of liposome aerosol suggest the possible benefit of it and of its more active derivative, 9-NC, in the treatment of lung, liver, kidney and brain cancer in humans.
Journal of Biological Chemistry | 2000
Feng He; Alexander Seryshev; Christopher W. Cowan; Theodore G. Wensel
The photoreceptor cGMP phosphodiesterase (PDE6) plays a key role in vertebrate vision, but its enzymatic mechanism and the roles of metal ion co-factors have yet to be determined. We have determined the amount of endogenous Zn2+ in rod PDE6 and established a requirement for tightly bound Zn2+ in catalysis. Purified PDE6 contained 3–4-g atoms of zinc/mole, consistent with an initial content of two tightly bound Zn2+/catalytic subunit. PDE with only tightly bound Zn2+ and no free metal ions was inactive, but activity was fully restored by Mg2+, Mn2+, Co2+, or Zn2+. Mn2+, Co2+, and Zn2+ also induced aggregation and inactivation at higher concentrations and longer times. Removal of 93% of the tightly bound Zn2+ by treatment with dipicolinic acid and EDTA at pH 6.0 resulted in almost complete loss of activity in the presence of Mg2+. This activity loss was blocked almost completely by Zn2+, less potently by Co2+ and almost not at all by Mg2+, Mn2+, or Cu2+. The lost activity was restored by the addition of Zn2+, but Co2+ restored only 13% as much activity, and other metals even less. Thus tightly bound Zn2+ is required for catalysis but could also play a role in stabilizing the structure of PDE6, whereas distinct sites where Zn2+ is rapidly exchanged are likely occupied by Mg2+ under physiological conditions.
Journal of Clinical Investigation | 2014
Ming Shan; Ran You; Xiaoyi Yuan; Michael V. Frazier; Paul Porter; Alexander Seryshev; Jeong Soo Hong; Li Zhen Song; Yiqun Zhang; Susan G. Hilsenbeck; Lawrence W. Whitehead; Nazanin Zarinkamar; Sarah Perusich; David B. Corry; Farrah Kheradmand
The development of emphysema in humans and mice exposed to cigarette smoke is promoted by activation of an adaptive immune response. Lung myeloid dendritic cells (mDCs) derived from cigarette smokers activate autoreactive Th1 and Th17 cells. mDC-dependent activation of T cell subsets requires expression of the SPP1 gene, which encodes osteopontin (OPN), a pleiotropic cytokine implicated in autoimmune responses. The upstream molecular events that promote SPP1 expression and activate mDCs in response to smoke remain unknown. Here, we show that peroxisome proliferator-activated receptor γ (PPARG/Pparg) expression was downregulated in mDCs of smokers with emphysema and mice exposed to chronic smoke. Conditional knockout of PPARγ in APCs using Cd11c-Cre Pparg(flox/flox) mice led to spontaneous lung inflammation and emphysema that resembled the phenotype of smoke-exposed mice. The inflammatory phenotype of Cd11c-Cre Pparg(flox/flox) mice required OPN, suggesting an antiinflammatory mechanism in which PPARγ negatively regulates Spp1 expression in the lung. A 2-month treatment with a PPARγ agonist reversed emphysema in WT mice despite continual smoke exposure. Furthermore, endogenous PPARγ agonists were reduced in the plasma of smokers with emphysema. These findings reveal a proinflammatory pathway, in which reduced PPARγ activity promotes emphysema, and suggest that targeting this pathway in smokers could prevent and reverse emphysema.
Inhalation Toxicology | 2002
Brian E. Gilbert; Alexander Seryshev; Vernon Knight; Cory Brayton
9-Nitrocamptothecin (9-NC) dilauroylphosphatidylcholine (DLPC) liposome aerosol was evaluated for potential toxicity in an 8-wk, subacute toxicity study in dogs. Fourteen adult dogs were divided into 2 groups with 10 animals in the 9-NC-DLPC treatment group and 4 animals in the DLPC-only vehicle control group. 9-NC-DLPC was administered to the animals using an Aerotech II nebulizer flowing at 10 L/min. Fullface exposures for 60 min were conducted for 5 consecutive days a week for 8 wk. The estimated deposited aerosol dose was 24.7 µg/kg/day. Animals in the vehicle control group received aerosolized DLPC only. Body weight, food consumption, urinalysis, in-life observations, hematology, plasma chemistry, and necropsy and histopathology were monitored before and during the treatment period and in a subset of animals for 2 wk following the end of treatment. Animals were observed for signs of pharmacologic and/or toxicologic effects three times on days of dosing and once daily on nondosing days. 9-NC-DLPC liposomes administered as a small-particle aerosol were determined to be nontoxic to dogs when given for 5 days/wk, for a duration of 8 wk. DLPC-only liposome also had no toxic effects.
Mucosal Immunology | 2011
Wendy Tai; Luz Roberts; Alexander Seryshev; J. M. Gubatan; C. S. Bland; R. Zabriskie; S. Kulkarni; Lynn Soong; I. Mbawuike; Brian E. Gilbert; Farrah Kheradmand; David B. Corry
All commercial influenza vaccines elicit antibody responses that protect against seasonal infection, but this approach is limited by the need for annual vaccine reformulation that precludes efficient responses against epidemic and pandemic disease. In this study we describe a novel vaccination approach in which a nanoparticulate, liposome-based agent containing short, highly conserved influenza-derived peptides is delivered to the respiratory tract to elicit potent innate and selective T cell-based adaptive immune responses. Prepared without virus-specific peptides, mucosal immunostimulatory therapeutic (MIT) provided robust, but short-lived, protection against multiple, highly lethal strains of influenza in mice of diverse genetic backgrounds. MIT prepared with three highly conserved epitopes that elicited virus-specific memory T-cell responses but not neutralizing antibodies, termed MITpep, provided equivalent, but more durable, protection relative to MIT. Alveolar macrophages were more important than dendritic cells in determining the protective efficacy of MIT, which induced both canonical and non-canonical antiviral immune pathways. Through activation of airway mucosal innate and highly specific T-cell responses, MIT and MITpep represent novel approaches to antiviral protection that offer the possibility of universal protection against epidemic and pandemic influenza.
Medical Mycology | 2011
Paul Porter; Sumanth Polikepahad; Yuping Qian; J. Morgan Knight; Wen Lu; Wendy Tai; Luz Roberts; Valentine Ongeri; Tianshu Yang; Alexander Seryshev; Stuart L. Abramson; George L. Delclos; Farrah Kheradmand; David B. Corry
Allergic asthma is an obstructive lung disease linked to environmental exposures that elicit allergic airway inflammation and characteristic antigen-specific immunoglobulin reactions termed atopy. Analyses of asthma pathogenesis using experimental models have shown that T helper cells, especially T helper type 2 (Th2) cells and Th2 cytokines such as interleukin 4 (IL-4) and IL-13, are critical mediators of airway obstruction following allergen challenge, but the environmental initiators of lung Th2 responses are less defined. Our studies demonstrate that fungal-derived proteinases that are commonly found in home environments are requisite immune adjuvants capable of eliciting robust Th2 responses and allergic lung disease in mice. We have further shown that common household fungi readily infect the mouse respiratory tract and induce both asthma-like disease and atopy to otherwise innocuous bystander antigens through the secretion of proteinases. These findings support the possibility that asthma and atopy represent a reaction to respiratory tract fungal infection, suggesting novel means for diagnosis and therapy of diverse allergic disorders.
Mucosal Immunology | 2015
Xiaoyi Yuan; Ming Shan; Ran You; Michael V. Frazier; Monica Jeongsoo Hong; Rick A. Wetsel; Scott M. Drouin; Alexander Seryshev; Li-zhen Song; Lorraine D. Cornwell; Roger D. Rossen; David B. Corry; Farrah Kheradmand
Exposure to cigarette smoke can initiate sterile inflammatory responses in the lung and activate myeloid dendritic cells (mDCs) that induce differentiation of T helper type 1 (Th1) and Th17 cells in the emphysematous lungs. Consumption of complement proteins increases in acute inflammation, but the contribution of complement protein 3 (C3) to chronic cigarette smoke-induced immune responses in the lung is not clear. Here, we show that following chronic exposure to cigarette smoke, C3-deficient (C3−/−) mice develop less emphysema and have fewer CD11b+CD11c+ mDCs infiltrating the lungs as compared with wild-type mice. Proteolytic cleavage of C3 by neutrophil elastase releases C3a, which in turn increases the expression of its receptor (C3aR) on lung mDCs. Mice deficient in the C3aR (C3ar−/−) partially phenocopy the attenuated responses to chronic smoke observed in C3−/− mice. Consistent with a role for C3 in emphysema, C3 and its active fragments are deposited on the lung tissue of smokers with emphysema, and smoke-exposed mice. Together, these findings suggest a critical role for C3a through autocrine/paracrine induction of C3aR in the pathogenesis of cigarette smoke-induced sterile inflammation and provide new therapeutic targets for the treatment of emphysema.
Journal of the American Chemical Society | 2005
Tatiana Y. Zakharian; Alexander Seryshev; Balaji Sitharaman; Brian E. Gilbert; Vernon Knight; Lon J. Wilson